Trial · NCT05616013
Outcomes41
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 41
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Body Weight at Week 48 | Baseline, Week 48 | All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome. | kilogram (kg) | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Waist Circumference at Week 48 | Baseline, Week 48 | All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome. | centimeter (cm) | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Waist Circumference at Week 72 | Baseline, Week 72 | |||
| SECONDARY | Change From Baseline in Total Body Fat Mass in Kilograms (kg) at Week 48 | Baseline, Week 48 | All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome. | kg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Total Body Fat Mass in kg at Week 72 | Baseline, Week 72 | |||
| SECONDARY | Change From Baseline in Body Fat Percentage at Week 48 | Baseline, Week 48 | All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome. | percentage of body fat | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Body Fat Percentage at Week 72 | Baseline, Week 72 | |||
| SECONDARY | Change From Baseline in Visceral Adipose Tissue (VAT), Subcutaneous Adipose Tissue (SAT) and Trunk Fat Mass by DXA at Week 48 | Baseline, Week 48 | All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome. | kg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in VAT, SAT and Trunk Fat Mass by DXA at Week 72 | Baseline, Week 72 | |||
| SECONDARY | Percentage of Participants With Reduction in Waist Circumference ≥ 5 cm at Week 48 | Week 48 | All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Reduction in Body Weight ≥ 5%, ≥ 10% and ≥15% at Week 48 | Week 48 | All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Reduction in Fat Mass ≥ 5% ≥ 10% ≥ 15% by DXA at Week 48 | Week 48 | All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Reduction in Fat Mass ≥ 10% With <5% Decrease (or an Increase) in Lean Mass by DXA at Week 48 | Week 48 | All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving >5 kg Weight Loss and Fat Loss Index (FLI) of >70%, >80%, and >90% by DXA at Week 48 | Week 48 | All randomized participants who received at least one dose of the study drug and had evaluable data for this outcome. | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Body Fat Mass by Bioelectrical Impedance Analysis (BIA) at Week 48 | Baseline, Week 48 | All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome. | kg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Body Fat Mass by BIA at Week 72 | Baseline, Week 72 | |||
| SECONDARY | Change From Baseline in Body Fat Percentage by BIA at Week 48 | Baseline, Week 48 | All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome. | percentage of body fat | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Body Fat Percentage by BIA at Week 72 | Baseline, Week 72 | |||
| SECONDARY | Change From Baseline in Lean Mass by DXA at Week 48 | Baseline, Week 48 | All randomized participants who received at least one dose of the study drug, had a baseline and at least one post- baseline value for this outcome. | kg | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Lean Mass by DXA at Week 72 | Baseline, Week 72 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05616013/outcomes